Sunday, November 1, 2026

health-technology

5 articles

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

GuideAI Health Corp.'s conditional Cboe Canada listing could force a full return of investor proceeds if exchange requirements go unmet. The company is building AI diagnostics for cardiovascular disease — the world's leading killer — at a moment when clinical AI firms globally face high barriers to public capital. A failed listing would unwind its entire post-combination structure.

LM Salvado•
U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

RadNet's adjusted EBITDA rose 36.3% year-over-year in Q1 2026, well ahead of its 22.1% revenue growth, driven by AI scheduling and diagnostic tools across its U.S. network. Advanced imaging volumes surged, with PET/CT up 35.2% and MRI same-center volume up 10.1%. The margin expansion offers a concrete financial reference point for hospital systems worldwide evaluating AI investment in radiology.

LM Salvado•
Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical secured regulatory approvals for its da Vinci 5 robotic system in Europe and Japan, unlocking markets worth $2.3 billion in annual surgical robotics spending. The company beat Q4 earnings forecasts while installing 415 systems globally, a 22% increase year-over-year. Force feedback and AI-powered features distinguish the new platform as competition intensifies across international markets.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com